Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

11 results
Display

Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Lee HW, Cho KJ, Park JY

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of disease. Until recently, systemic treatment options that showed survival benefits in HCC have been limited to tyrosine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

Choi J, Lee SY

Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment. However, immune-related adverse effects (irAEs) have also increased with the exponential increase in the use of ICIs. ICIs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy

Kim KH, Kim CG, Shin EC

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis

Oh SJ, Lee J, Kim Y, Song KH, Cho E, Kim M, Jung H, Kim TW

Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
IL-17-Producing Cells in Tumor Immunity: Friends or Foes?

Kuen DS, Kim BS, Chung Y

IL-17 is produced by RAR-related orphan receptor gamma t (RORγt)-expressing cells including Th17 cells, subsets of γδT cells and innate lymphoid cells (ILCs). The biological significance of IL-17-producing cells is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity

Lee HW, Chung YS, Kim TJ

The γδ T cells are unconventional lymphocytes that function in both innate and adaptive immune responses against various intracellular and infectious stresses. The γδ T cells can be exploited as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Kim JH, Kim BS, Lee SK

Tregs have a role in immunological tolerance and immune homeostasis by suppressing immune reactions, and its therapeutic potential is critical in autoimmune diseases and cancers. There have been multiple studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

Jeong S, Park SH

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation

Im SJ, Ha SJ

Acute viral infection or vaccination generates highly functional memory CD8 T cells following the Ag resolution. In contrast, persistent antigenic stimulation in chronic viral infection and cancer leads to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Coalition Forces of Immunologists and Oncologists for Defeating Cancer

Shin EC

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr